Ubs Group Ag Pliant Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLRX
# of Institutions
168Shares Held
63.2MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$79.4 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$66.1 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.83MShares$64.3 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$46.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$42.5 Million2.34% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $647M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...